We use cookies to ensure that we give you the best experience on your website. If you continue without changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use. For Medical questions regarding any BTG products, please contact medical.services@btgplc.com
BTG Vascular sets the standard for vascular therapies through evidence based innovation, predictable and cost-effective procedures, and strong safety profiles that improve patient outcomes and help make the most challenging cases easier.
Fast, intraluminal occlusion crossing. BTG Crossing Devices provide physician support to make tough crossings easier. Staying true lumen opens revascularization possibilities, improves patient safety, comfort and healthcare costs.
Resource of case studies, clinical trial data and in-servicing videos for the family of EKOS™ devices.
EKOS OPTALYSE Study Summary
The EKOS device with Acoustic Pulse Thrombolysis™ is the first endovascular device cleared by the FDA and CE marked for the treatment of Pulmonary Embolism (PE).
EKOS™ is setting the standard for PE treatment safety and efficacy, again. With the EKOS™ treatment’s successful very-low dose and short duration regimens in the OPTALYSE PE trial and favorable long term data results point to a paradigm-changing approach for PE treatment.
15 Nov AIM
17 Nov VEITH
24 Feb APCCVIR
14 Feb A Retrospective Study of Medicare claim ...
03 Dec Arizona Patients Successfully Receive th...
20 Nov Recommended Cash Offer for BTG plc by Bo...
Information
28 Apr OPTALYSE PE Results Presented at Society...
17 May Healthcare Player BTG on lookout for acq...
05 Apr NICE highlights potential role of TheraS...